🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

#ESMO24 Neoadjuvant nivolumab/relatlimab or nivolumab/ipilimumab in TNBC with high TILs: BELLINI trial 🔍stage I-II, node negative, TILs ≥50%, 30 pts pCR Nivo+IPI➡️33% Nivo+RELA➡️47% 💥Remarkable efficacy of chemotherapy-free immunotherapy for immunogenic TNBC

Promising results with neoadjuvant nivo/relatlimab (LAG3 mAb) for mostly cT1c TNBC with high TILs: 47% pCR rate, 73% MPR. Immune toxicities remain an issue, with a case of diabetes mellitus. Terrific work from the team of MarleenKokLab — concomitant Nature Medicine publication

👇Wij zoeken een ervaren, enthousiaste, pro-actieve en flexibele Project Manager voor een groot, internationaal onderzoek om biomarker (TILs) naar de kliniek te brengen. werkenbijavl.nl/vacatures/clin…

Very excited that we see a 33% pCR rate with only 6 weeks of immunotherapy without chemo in TIL high TNBC. A lay version of our story👇. The Netherlands Cancer Institute TILs Working Group Nature Medicine

#ceasefire now! ❤️‍🩹

A very impactful #ESMO24. Thanks Rebecca Dent and great ESMO staff ESMO - Eur. Oncology Kate Kronig! Minor note: Nature Medicine had even more concomitant papers of which 2 from The Netherlands Cancer Institute

Clinical Cancer Research is seeking a new Editor-in-Chief! Apply by September 30, 2024. Find out more: bit.ly/3zxjJ4U

Best break-out session ever on TME in lobular BC! Important especially since pts with ILC are often excluded from immunotherapy trials. Thanks for terrific organisation and location Christine Desmedt ELBCC #ilcsymposium Dr. Steffi Oesterreich

Had a fantastic meeting at the #ILCsymposium in beautiful Leuven, Belgium organized by Christine Desmedt and her team! Lots to think about, and lot more progress that needs to be made! Dr. Steffi Oesterreich Adrian Lee

Thanks ACIR for putting our work on neoadjuvant immunotherapy for TNBC in the spotlight Rianne Rolfes Manon de Graaf @DiLa_lab Nature Medicine

👀 We're looking for a junior group leader! Join our innovative, curiosity-driven institute in a collaborative, international environment. Full freedom to pursue your research, competitive salary & relocation support. 📅 Apply by Dec 1 Info & application: bit.ly/3BLA3j8

This will be amazing session #SABCS24 with stellar speakers and immune biomarkers inc TILs making their way to the clinic!

On my way to one of the best conferences on translational cancer research! #MAP24 🚆🚆💚💚

Mensen die naar ons land vluchten voor hun leven, voor de toorn van kwaadaardige regimes die we bestrijden bijvoorbeeld, wil de coalitie vanaf nu elke kans ontnemen nog iets van hun leven te maken…. Er is inderdaad een ernstige crisis gaande in ons land. Een morele crisis.

Stellar line up of speakers and spot on discussions and clinical cases! In the beautiful town of Padua🇮🇹 #AIBCC24 with Mafalda Oliveira Maria Vittoria Dieci @prat_aleix Hope Rugo and many others!

Fantastic PhD program at amazing institution The Netherlands Cancer Institute 👇

This is well-deserved! Congrats Karin de Visser 🥳🥳. She was one of the first scientists recognizing the importance of immune cells in breast tumors. Thanks to key leaders like Karin we now start doing trials specific for BC with high TILs #OPTImal study The Netherlands Cancer Institute TILs Working Group

Recent Nature paper on phase of menstrual cycle at start of breast cancer chemo suggests that this can affect chemo-sensitivity. More research needed on how this can result in cycle-driven-chemo-start. 💊💉Congrats ⁦Van Rheenen Lab⁩ ⁦The Netherlands Cancer Institute⁩ nature.com/articles/s4158…

Excited to present 🎤 first data #SABCS24 from TONIC2. Follow-up from nature.com/articles/s4159…. Are immune induction with dox or cisplatin indeed benefiting pts? Veerle Geurts at P1-7-30 and new data on acquired resist🔬 to aPD1 at PS17-09 The Netherlands Cancer Institute OncoAlert Nature Medicine